SOUTH SAN FRANCISCO, Calif., Oct. 19, 2017 -- Five Prime Therapeutics, Inc. (NASDAQ:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, will report its third quarter 2017 financial results on Monday, November 6, 2017, after the U.S. financial markets close. Five Prime will host a conference call and live audio webcast on Monday, November 6, 2017, at 4:30 p.m. (ET)/1:30 p.m. (PT) to discuss the company's financial results and provide a general business update.
The live audio webcast may be accessed through the "Events & Presentations" page in the "Investors" section of the company's website at www.fiveprime.com. Alternatively, participants may dial (877) 878-2269 (domestic) or (253) 237-1188 (international) and refer to conference ID 95493696.
The archived conference call will be available on Five Prime's website beginning approximately two hours after the event and will be archived and available for replay for at least 30 days after the event.
About Five Prime
Five Prime Therapeutics, Inc. discovers and develops innovative therapeutics to improve the lives of patients with serious diseases. Five Prime's comprehensive discovery platform, which encompasses virtually every medically relevant extracellular protein, positions it to explore pathways in cancer, inflammation and their intersection in immuno-oncology, an area with significant therapeutic potential and a growing focus of the company's R&D activities. Five Prime has entered into strategic collaborations with leading global pharmaceutical companies and has promising product candidates in clinical and late preclinical development. For more information, please visit www.fiveprime.com.
CONTACT:
Derek Cole
Investor Relations Advisory Solutions
720-785-4497
[email protected]


Samsung Signals Comeback With HBM4 Chips as AI Market Heats Up
Boeing Secures Major $2.7 Billion U.S. Military Contract for Apache Helicopter Support
Air China Orders 60 Airbus A320neo Jets in $9.5 Billion Deal as Airbus Strengthens Grip on China Market
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital
Anghami Stock Soars After Strong H1 2025 Results, Revenue Nearly Doubles on OSN+ Integration
Baidu Shares Surge as Company Plans Kunlunxin AI Chip Spin-Off and Hong Kong Listing
SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round
Google Accelerates AI Infrastructure With Ironwood TPU Expansion in 2026
Target Stock Rallies as Activist Interest Sparks Hopes for Strategic Change
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics
Neuralink Plans Automated Brain Implant Surgeries and Mass Production by 2026
Lockheed Martin Secures $328.5 Million U.S. Defense Contract for Advanced Systems Supporting Taiwan Air Force
Disney Agrees to $10 Million Settlement Over Child Privacy Violations on YouTube
Starlink Plans Satellite Orbit Reconfiguration in 2026 to Boost Space Safety
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch 



